cytosorbents.com Open in urlscan Pro
2606:4700:10::ac43:14a1  Public Scan

Form analysis
2 forms found in the DOM

GET /

<form action="/" method="GET" class="component-input-search">
  <span class="icon-search"></span>
  <input data-rest-url="https://cytosorbents.com/wp-json/" type="search" autocomplete="off" class="copy-md" name="s" value="" placeholder="Search...">
  <div class="search-result-container d-flex" style="width: 511px; top: 40px;">
    <div class="search-for copy-xs">
      <span class="prefix">Search for</span> "<span class="value"></span>"
    </div>
    <ul class="list">
    </ul>
    <button class="component-button button secondary sm " aria-label="See all 24 results">
      <span class="icon-arrow-right"></span>
      <span class="label">See all 24 results</span>
    </button>
  </div>
</form>

GET /

<form action="/" method="GET" class="component-input-search">
  <span class="icon-search"></span>
  <input data-rest-url="https://cytosorbents.com/wp-json/" type="search" autocomplete="off" class="copy-md" name="s" value="" placeholder="Search...">
  <div class="search-result-container d-flex" style="width: 0px; top: 0px; left: 0px;">
    <div class="search-for copy-xs">
      <span class="prefix">Search for</span> "<span class="value"></span>"
    </div>
    <ul class="list">
    </ul>
    <button class="component-button button secondary sm " aria-label="See all 24 results">
      <span class="icon-arrow-right"></span>
      <span class="label">See all 24 results</span>
    </button>
  </div>
</form>

Text Content

SHARE


Not all products are available in the USA. Click here for a regulatory status
overview.
Search for ""
See all 24 results

 * CytoSorbents & Technology
    * CytoSorbents & Hemoadsorption
    * Our Innovation
    * Our current Solutions
      * Overview
      * CytoSorb
      * PuriFi
      * ECOS
      * VetResQ
    * Our Team of Experts
    * Voices around the world
    * Our featured Pipeline
      * DrugSorb
      * HemoDefend

 * For Healthcare Professionals
    * CytoSorb Therapy
      * Overview
      * Critical Care
      * Cardiovascular
      * Liver
      * Kidney
    * Training & Education
      * Support Materials
      * Literature Database
      * Studies and Registries
      * Reimbursement
    * FAQ

 * For Patients & Families
    * Blood Purification explained
    * Our Therapy
   
   ACHIEVED: 1,000 ENTRIES IN CYTOSORB LITERATURE DATABASE
   
   read blog post
 * About us
    * Locations
    * Executive Management
    * Board of Directors
    * Distributors
    * Our Partners
    * Support
    * Careers
   
   ACHIEVED: 1,000 ENTRIES IN CYTOSORB LITERATURE DATABASE
   
   read blog post
 * For Investors
 * News & Media
    * Blog
    * Events
    * Mediacenter
   
   ACHIEVED: 1,000 ENTRIES IN CYTOSORB LITERATURE DATABASE
   
   read blog post

Search for ""
See all 24 results

 * CytoSorbents & Technology
   * CytoSorbents & Hemoadsorption
   * Our Innovation
   * Our current Solutions
     * Overview
     * CytoSorb
     * PuriFi
     * ECOS
     * VetResQ
   * Our Team of Experts
   * Voices around the world
   * Our featured Pipeline
     * DrugSorb
     * HemoDefend
 * For Healthcare Professionals
   * CytoSorb Therapy
     * Overview
     * Critical Care
     * Cardiovascular
     * Liver
     * Kidney
   * Training & Education
     * Support Materials
     * Literature Database
     * Studies and Registries
     * Reimbursement
   * FAQ
 * For Patients & Families
   * Blood Purification explained
   * Our Therapy
 * About us
   * Locations
   * Executive Management
   * Board of Directors
   * Distributors
   * Our Partners
   * Support
   * Careers
 * For Investors
 * News & Media
   * Blog
   * Events
   * Mediacenter

EMPOWERING INDEPENDENT CYTOSORB® THERAPY

*NOT AVAILABLE IN THE US

 

CE-MARKED UNDER MDR SINCE 06/2024

Take care of your patients wherever and whenever they need the proven benefits
of CytoSorbents’ hemoadsorption therapies.

 

PuriFi is specifically designed for application of CytoSorbents’ hemoadsorption
solutions, allowing rapid training and quick and easy setup when needed.
Designed with maximum mobility in mind, it can be used in the Emergency Room, in
the Intensive Care Unit, or in Intermediate Care settings.





PURIFI ATTRIBUTES

Intuitive touchscreen interface

Maintenance-free pressure monitoring

Pre-assembled adult and pediatric line kit

Auto-leveling bubble catcher

Temperature management option

Rapid set-up in 10min and automated priming




OVERCOME CHALLENGES BY USING CYTOSORB IN STANDALONE CONFIGURATIONS

PROVEN SAFETY

Over 200,000 treatments administrated over the last ten years

 

MOST PEER-REVIEWED ADSORBER

Over 800 publications, abstracts, poster, manuscripts, and other resources.

IMPROVED PATIENT OUTCOMES

With demonstrated efficacy across cardiovascular, kidney, liver, and critical
care.




CONTACT US TO DISCOVER MORE
ABOUT PURIFI

Get in touch!





PURIFI AT A GLANCE



Watch this video on YouTube




ADDITIONAL INFORMATION

STANDALONE BROCHURE

Download file

SPEC SHEET

Download file

QUICK SET-UP GUIDE

Download file

REFERENCES

 * Mitzner et al. J Clin Med. 2023;12(23):7199
 * Schmoeckel et al., J Throm & Thrombolysis 2024; epub
 * Doukas et al., J Clin Med 2023; 12:546
 * Haidari et al., ICV&TS 2023; 36(1):ivad010
 * Nemeth et al., ESC Heart Failure 2024; 11(2):772-782
 * Grafe et al., Ren Fail 2023; 45(2):2259231
 * Haselwanter et al., Sci Rep 2024; 14(1):11309
 * Jansen et al., Critical Care 2023; 27(1):117
 * Akil et al., J Clin Med 2022; 11(20):5990

Show more

CytoSorbents


VOICES AROUND THE WORLD




Watch this video on YouTube


89
91
Kidney

DR. FILIPO AUCELLA

Italy, San Giovanni

When we started to use CytoSorb®, we were very impressed by the rapid decrease
of myoglobin concentrations, and the renal damage also improved very rapidly.

89

Cardiovascular

DR. MARIA GRAZIA CALABRO

Italy, Milan

CytoSorb is effective in reducing bilirubin, creatinine, and lactate in patients
who are critically ill, mainly due to cardiogenic shock.

view more


Watch this video on YouTube


89
95
Critical Care

DR. TOBIAS HÜBNER

Switzerland, Münsterlingen

The reason for us to use CytoSorb in the ICU was the lack of treatment options.
We never had anything in sepsis, and CytoSorb® is the new star on the horizon.



Watch this video on YouTube


89
91
Critical Care

DR. GABRIELLA BOTTARI

Italy, Rome

We have applied CytoSorb in critical ill children with septic shock, with very
good results.

Liver

DR. MIHAI POPESCU

Romania, Bucharest

Our results show a potential benefit of CytoSorb in rebalancing liver function
in patients with liver failure compared to MARS.

view more


Watch this video on YouTube


89
91
Cardiovascular

DR. SERDAR GUNAYDIN

Turkey, Ankara

One of the most important indications for us to use CytoSorb® in is cardiac
surgery, as it has also been cited in many guidelines.

89

Critical Care

DR. WILLEM BROUWER

The Netherlands, Rotterdam

Intervention with CytoSorb may be associated with decreased all-cause mortality
at 28 days compared to continuous renal replacement therapy alone.

view more


Watch this video on YouTube


81
83
About CytoSorbents

PROF. JEAN LOUIS VINCENT

Belgium, Brussels

I would like to send my congratulations on the 10th anniversary of CytoSorb®. It
is great how you have created a new way of blood purification therapy.

89

Critical Care

JUAN CARLOS RUIZ-RODRIGUEZ

Spain, Barcelona

This case highlights that cytokine hemoadsorption can lead to a rapid decrease
in IL-10 levels, and significant hemodynamic improvement was achieved.

view more
89
91
Critical Care

DR. GABRIELLA BOTTARI

Italy, Rome

Hemoperfusion with CytoSorb in combination with continuous kidney renal therapy
is a valuable therapeutic option in sepsis-associated acute kidney injury.

view more
89

Critical Care

DR. ASKHAT SAPAROV

Kazakhstan, Astana

CytoSorb was safe and well-tolerated in a pediatric patient and has proven its
value as an adjuvant therapy for sepsis in pediatric patient populations.

view more


Watch this video on YouTube


89
91
Critical Care

PROF. PETER PICKKERS

The Netherlands, Nijmegan

The treatment with the CytoSorb® adsorber does reduce circulating concentrations
at day one.

89

Critical Care

DR. ABDULRAHMAN ALHARTHY

Saudi Arabia, Riyadh

In this retrospective case series, CRRT with CytoSorb provided a safe rescue
therapy in COVID-19 with associated AKI, ARDS, sepsis, and hyperinflammation.

view more
89

Critical Care

DR. KAI SINGBARTL

USA, Phoenix

The case represents the first successful application of CytoSorb in severe
refractory neurotoxicity following treatment with chimeric-antigen-receptor T
cells.

view more
89

Cardiovascular

DR. HENRIETTE ROED-UNDLIEN

Norway, Oslo

In this in vitro study, apixaban levels were effectively reduced, and the
clotting time and thrombin generation assays were normalized by the use of
CytoSorb.

view more
89

Critical Care

DR. ALEKSANDR BUROV

Russia, Moskow

This case series demonstrates that combined blood purification therapy including
CytoSorb may have a role for septic shock patients with primary brain injury.

view more
Critical Care

PROF. JW AWORI HAYANGA

USA, Morgantown

In COVID-19 ARDS on VV-ECMO + hemoadsorption, 90-day survival 74% and early
intervention associated with shorter organ support, supporting “enhanced lung
rest”.

view more
89

Cardiovascular

DR. HAIDER GHAIDAN

Sweden, Lund

CytoSorb restored lung function and reduced PGD in lung transplantation. We
suggest this treatment will increase tolerability of donor lungs in recipients.

view more
Critical Care

DR. PAWEL PIWOWARCZYK

Poland, Lublin

CytoSorb Therapy was able to facilitate long-term regain of balance between
inflammatory process, cytokine production, and bilirubin turnover in the liver.

view more
89

Critical Care

DR. ANNA KRAKOWIAK

Poland, Lodz

In the event of poisoning with inorganic mercury compounds, CRRT using CytoSorb
as an extracorporeal blood purification method may be considered.

view more
89

Critical Care

DR. VANJA PERSIC

Slovenia, Ljubljana

Use of CytoSorb in shocked SIRS patients was associated with rapid IL-6 decrease
and hemodynamic improvement, with improved observed vs predicted survival.

view more
89

Critical Care

DR. SIMAO RODEIA

Portugal, Lisbon

Cytokine adsorption therapy with CytoSorb was employed with no direct
complications, and helped control the inflammatory state.

view more
89

Critical Care

DR. CHRISTOPHER RUGG

Austria, Innsbruck

Catecholamines decreased within 24 h after initiation of CytoSorb Therapy;
in-hospital mortality was significantly lower in the CytoSorb group (35.7% vs
61.9%).

view more
Cardiovascular

PERFUSIONIST ANNA HOLMEN

Sweden, Gothenburg

The accumulated norepi dose in the CytoSorb gp was half or less at all postop
time points compared to controls..with significantly lower need for RBC.

view more
89

Critical Care

ASSOC. PROF. BERNA KAYA UGUR

Turkey, Gaziantep

Use of CytoSorb achieved significant decreases in endocan, copeptin, IL-6,
procalcitonin and C-reactive protein levels.

view more
89

Kidney

DR. JOHN FERDINAND

UK, Cambridge

Our data suggest that adsorption of pro-inflammatory mediators from perfusate
with CytoSorb represents potential intervention which may improve organ
viability.

view more
89

Liver

PROF. DANA TOMESCU

Romania, Bucharest

The use of CytoSorb in patients with severe acute pancreatitis was associated
with improved hemodynamics and decreased inflammatory markers.

view more
89

Liver

DR. AROSHA MINORI GUNASEKERA

Sri Lanka, Colombo

This patient with acute liver failure was managed successfully with supportive
therapy, aided by CytoSorb hemoadsorption and therapeutic plasma exchange.

view more
89

Cardiovascular

DR. ENDRE NEMETH

Hungary, Budapest

Intraoperative hemoadsorption associated with better hemodynamics, lower post-op
AKI and RRT, stable bilirubin, and shorter mechanical ventilation time and ICU

view more
89

Critical Care

DR. FATIME HAWCHAR

Hungary, Szeged

The first trial to investigate the effects of early extracorporeal cytokine
adsorption treatment in septic shock applied without renal replacement therapy.

view more
89

Kidney

DR. WUN FUNG HUI

Hong Kong, Hong Kong

Hemoadsorption with CytoSorb can be considered as an adjunctive therapy for
children with severe rhabdomyolysis-associated acute kidney injury.

view more
89

Critical Care

DR. MAROUA EID

France, Angers

This case describes the successful use of CytoSorb with CRRT and extracorporeal
life support in a combined way to overcome a critical phase of septic shock.

view more
89

Critical Care

DR. MARINE PEYNEAU

France, Paris

CytoSorb appears to be safe and promising to fight post-lung transplantation
inflammation, and should be re-evaluated in a larger study.

view more
89

Cardiovascular

DR. DANIEL LOVRIC

Croatia, Zagreb

This is the first study showing an increase in urinary output and a trend
towards better survival among patients on VA ECMO treated with CytoSorb.

view more
89

Critical Care

PROF. PEDJA KOVACEVIC

Bosnia and Herzegovina, Banja Luka

This case series describes potential positive effects of hemoadsorption in
preventing the development of systemic hyperinflammation after vvECMO in ARDS.

view more
89
95
Cardiovascular

CERTIFIED CLINICAL PERFUSIONIST MARTIN CLERICI

Argentina, Buenos Aires

Intraoperative use of CytoSorb® in an endocarditis patient with extensive
cardiovascular history was associated with improvements in the hemodynamic
situation.

view more


Watch this video on YouTube


89
91
Critical Care

PROF. DOREL SANDEC

Romania, Timisoara

We treated more than 75 patients with CytoSorb® because we realized, we feel, we
see, we measure a significant effect on the evolution of the patient.



Watch this video on YouTube


89
91
Critical Care

DR. VOYKA GORJUP

Slovenia, Ljubljana

The most prominent clinical effect is the lowering of vasopressors, hemodynamic
stability, lowering of interleukins and in those patients who are on vvECMO…



Watch this video on YouTube


89
91
Critical Care

DR. CANDIDO AMADOR

Panama, Panama City

In my experience the vasopressor doses decreased, biomarkers of sepsis (…) and
the inflammatory response as well as multiple organ function improved.

89

Critical Care

ASSOC. PROF. MONIR SADAT HAKEMI

Iran, Tehran

It seems that applying the CytoSorb in combination with CRRT in ICU septic
patients with AKI is correlated with a significant decrease in mortality.

view more


Watch this video on YouTube


89
91
Critical Care

DR. YATIN MEHTA

India, Gurgaon

CytoSorb is indicated for use in conditions where elevated levels of cytokine
and/or bilirubin and/or myoglobin exist.



Watch this video on YouTube


89
91
Cardiovascular

DR. L. CHRISTIAN NAPP

Germany, Hannover

In the most critically ill patients on ECMO support, we observed a drop in
catecholamine demand and an improvement in clinical state on ECMO.



Watch this video on YouTube


89
91
Critical Care

PROF. STEFFEN MITZNER

Germany, Rostock

What strikes you first is that you can stabilize patients in septic shock.

Legals
 * Imprint
 * Privacy Policy
 * Regulatory Status Overview
 * Terms of use
 * Disclaimer
 * Cookie Settings

More Details
 * Voices around the world
 * Therapy Overview
 * Product Overview

More Details
 * Careers
 * FAQ
 * Literature Database
 * Support

©2024 CytoSorbents Europe GmbH | All Rights Reserved

Support Literature
Switch language English German (Deutsch)
We use cookies and other technologies.
This website uses cookies and similar functions to process end device
information and personal data. The processing serves the integration of content,
external services and elements of third parties, statistical
analysis/measurement, personalized advertising and the integration of social
media.
Decline Settings Accept all
Imprint Data protection notice
Powered by CCM19
Please select guidelines to be admitted
Technically necessary (3) ?
Here you can find all technically necessary scripts, cookies and other elements
that are necessary for the operation of the website or the operator has a
legitimate interest according to DSGVO Art6, para. 1.
Advertisements / Ads (1) ?
Google Ads and various other ads providers are used whose conversion tracking is
integrated here. If you agree here, personal data will be transferred to the ads
providers.
Social media (1) ?
All social media channels used by the current page are listed here.
Other (1) ?
Here you can find other scripts and cookies that do not fit into any of the
above categories.
Cancel Save All accept